VERU (verupharma.com) קצב צמיחת רווח למניה בשנה הנוכחית

Veru Inc. biotechnological capacities are operating strictly on schedule, ensuring timely equipment calibration and plant redundancy. Revenues are generated through the sale of women's health products and promising oncology drugs. The company focuses on prostate and breast cancer therapies, including the maintenance of muscle mass. The 12-month relative EPS growth rate reflects a trend where the value stands at 47.30.

This indicator measures the annual growth of earnings per share, reflecting the rate of change in the business's net yield. Investors utilize this metric to assess capital resilience against market volatility and shocks. By analyzing the EPS YoY percentage shift, one can determine the efficiency of operational expense management. For Veru Inc. (VERU), such volatility is mitigated by the presence of patented oncology drugs. Stable sales of medical formulas ensure the predictability of this metric.